Contact
Please use this form to send email to PR contact of this press release:
Lion Biotechnologies Announces First Patient Dosed in Phase 2 Trial of LN-145 for Head and Neck Cancer
TO:
Please use this form to send email to PR contact of this press release:
Lion Biotechnologies Announces First Patient Dosed in Phase 2 Trial of LN-145 for Head and Neck Cancer
TO: